EN
Sai Life Sciences Limited Just Beat Revenue By 11%: Here's What Analysts Think Will Happen Next
Shareholders of Sai Life Sciences Limited (NSE:SAILIFE) will be pleased this week, given that the stock price is up 15% to ₹1,785 following its latest quarterly results. It was a mildly positive result, with revenues exceeding expectations at ₹6.6b, while statutory earnings per share (EPS) of ₹16.43 were in line with analyst forecasts. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.
Taking into account the latest results, the consensus forecast from Sai Life Sciences' seven analysts is for revenues of ₹26.2b in 2027. This reflects a solid 11% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 13% to ₹19.97. Before this earnings report, the analysts had been forecasting revenues of ₹26.2b and earnings per share (EPS) of ₹19.97 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Sai Life Sciences
The analysts reconfirmed their price target of ₹1,579, showing that the business is executing well and in line with expectations. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Sai Life Sciences at ₹1,620 per share, while the most bearish prices it at ₹1,500. This is a very narrow spread of estimates, implying either that Sai Life Sciences is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Sai Life Sciences' past performance and to peers in the same industry. It's clear from the latest estimates that Sai Life Sciences' rate of growth is expected to accelerate meaningfully, with the forecast 24% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 15% over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 17% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Sai Life Sciences to grow faster than the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Sai Life Sciences going out to 2029, and you can see them free on our platform here.
That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Sai Life Sciences , and understanding this should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.